Panagora Asset Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Panagora Asset Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5,501	Closed	-$76K	–	2523
2018 Q2	$76K	Sell	5,501 -6,739	-55%	-$80K	﹤0.01%	1930
2018 Q1	$111K	Buy	+12,240	New	+$67.5K	﹤0.01%	1829
2017 Q4	–	Sell	-250,421	Closed	-$353K	–	2400
2017 Q3	$353K	Sell	250,421 -67,435	-21%	-$94K	﹤0.01%	1473
2017 Q2	$477K	Buy	317,856 +181,722	+133%	+$390K	﹤0.01%	1366
2017 Q1	$350K	Hold	136,134	–	–	﹤0.01%	1476
2016 Q4	$347K	Hold	136,134	–	–	﹤0.01%	1570
2016 Q3	$421K	Buy	136,134 +64,734	+91%	+$202K	﹤0.01%	1505
2016 Q2	$229K	Buy	71,400 +3,295	+5%	+$12.1K	﹤0.01%	1621
2016 Q1	$211K	Buy	+68,105	New	+$222K	﹤0.01%	1635
2013 Q3	–	Sell	-1,483	Closed	-$19K	–	2405
2013 Q2	$19K	Buy	+1,483	New	+$20K	﹤0.01%	2191

Other funds holding ECYT

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Panagora Asset Management's ECYT Position: Q3 2018 in Review

Panagora Asset Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2018, closing a stake of 5,501 shares — an estimated $76K sold.

Panagora Asset Management first reported a position in ECYT in Q2 2013 and held it in 10 quarters. The position peaked at $477K in Q2 2017. 139 funds tracked by Wall St. Rank hold ECYT as of Q3 2018.

Panagora Asset Management reported no remaining Endocyte, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Panagora Asset Management sold 5,501 Endocyte, Inc. Common Stock shares in Q3 2018, an estimated $76K.
Panagora Asset Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 10 quarters.
Panagora Asset Management's Endocyte, Inc. Common Stock position peaked at $477K in Q2 2017.
139 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2018.

Based on Panagora Asset Management's 13F filing for Q3 2018, filed 13 Nov 2018.